This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
What's new
Congresses & Events
21 March, 2025
Congresses & Events
20 March, 2025
Congresses & Events
18 March, 2025
Congresses & Events
16 March, 2025
Congresses & Events
15 March, 2025
Clinical Trials
12 March, 2025
Status: Terminated
Congresses & Events
6 March, 2025
The global, randomized Phase III COMMODORE 1 study showed similar safety and exploratory efficacy for crovalimab▼ vs eculizumab in randomized patients who received prior eculizumab treatment; this study also enrolled non-randomized patients who switched from ravulizumab to crovalimab▼. This poster reports efficacy and safety data from the COMMODORE 1 ravulizumab switch cohort, with a median treatment duration of approximately 2 years.
Congresses & Events
6 March, 2025
At the primary analysis, the global, randomized, Phase III COMMODORE 1 study showed that crovalimab▼ was well tolerated and had similar exploratory efficacy in patients with paroxysmal nocturnal hemoglobinuria who switched from eculizumab to crovalimab▼ compared with those who continued receiving eculizumab. This poster reports long-term efficacy and safety data from COMMODORE 1, with a median follow-up duration of 2 years.
Congresses & Events
6 March, 2025
At the primary analysis, the global, randomized, Phase III COMMODORE 2 study demonstrated the non-inferior efficacy of crovalimab▼ vs eculizumab for co-primary efficacy endpoints of hemolysis control and transfusion avoidance in patients naive to complement inhibition, with a comparable safety profile. This poster reports long-term efficacy and safety data from COMMODORE 2, with a median follow-up duration of 2 years.
Congresses & Events
6 March, 2025
The Phase III BEAT-SC study is evaluating bevacizumab + atezolizumab and carboplatin/cisplatin and etoposide (ACE) vs placebo + ACE in patients with untreated ES-SCLC from Japan and China. This presentation reports the third OS interim analysis and additional updated clinical data from BEAT-SC.
Ask us a question and request information about Roche products or services.
If you have experienced potential side effects with a Roche product you can report it here.
If you suspect a potential defect or a Roche product has not met your expectations you can report it here.
Request an assessment if your product was stored outside the recommended temperature range.
On this global platform you will find tailored, evidence-based, balanced, and up-to-date medical information from Roche.This website is intended to provide medical information relating to questions asked about Roche medicines.
This website is not country specific and therefore may contain medical information on Roche medicines that is not applicable to your country. Please refer to your country prescribing information and local package insert.
Some medical information contained on this site may not be consistent with the locally approved indications for the specific Roche medicine. If you are a patient on a Roche medicine, please contact your treating doctor for medical support and before making any changes to your treatment.